Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma.

Abstract

Mantle-cell lymphoma (MCL) is a B-cell tumour with a usually poor prognosis, characterized by the proliferation of small cleaved lymphocytes with a diffuse growth pattern. We report a polymerase chain reaction-based analysis of minimal residual disease in a patient who achieved complete remission after allogeneic blood cell transplantation (BCT). Rearrangement of the immunoglobulin heavy-chain genes was used to generate a lymphoma-specific molecular marker. Lymphoma cells were not detectable in a bone marrow sample collected 12 months after BCT. Our findings suggest that allogeneic BCT may offer a curative approach to MCL.

• Authors: P Corradini, M Ladetto, M Astolfi, C Voena, C Tarella, A Bacigalupo, A Pileri
• Journal: British journal of haematology (Br J Haematol) Vol. 94 Issue 2 Pg. 376-8 (Aug 1996) ISSN: 0007-1048 [Print] England
• PMID: 8759900 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Adult
• Blood Component Transfusion (methods)
• Humans
• Lymphoma, Non-Hodgkin (therapy)
• Male
• Neoplasm, Residual
• Pilot Projects
• Polymerase Chain Reaction
• Remission Induction
• Transplantation, Homologous